Mereo BioPharma Group (MREO) Expected to Announce Quarterly Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Mereo BioPharma Group to post earnings of $0.02 per share for the quarter.

Mereo BioPharma Group Trading Down 7.0 %

Shares of NASDAQ:MREO opened at $2.38 on Monday. The firm’s 50 day moving average price is $2.79 and its 200-day moving average price is $3.55. Mereo BioPharma Group has a twelve month low of $2.25 and a twelve month high of $5.02.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Monday, January 13th. Lifesci Capital began coverage on Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 target price on the stock. Jefferies Financial Group assumed coverage on Mereo BioPharma Group in a research report on Friday, December 6th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $7.83.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.